Merck Retained Earnings (Accumulated Deficit) 2012-2026 | MRK

Merck retained earnings (accumulated deficit) for the quarter ending March 31, 2026 were $72.231B, a 17.67% increase year-over-year.

  • Merck retained earnings (accumulated deficit) for 2024 were $63.069B, a 17.02% increase from 2023.
  • Merck retained earnings (accumulated deficit) for 2023 were $53.895B, a 11.76% decline from 2022.
  • Merck retained earnings (accumulated deficit) for 2022 were $61.081B, a 13.75% increase from 2021.

Merck Retained Earnings (Accumulated Deficit) 2012-2026 | MRK

  • Merck retained earnings (accumulated deficit) for 2024 were $63.069B, a 17.02% increase from 2023.
  • Merck retained earnings (accumulated deficit) for 2023 were $53.895B, a 11.76% decline from 2022.
  • Merck retained earnings (accumulated deficit) for 2022 were $61.081B, a 13.75% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B